このエントリーをはてなブックマークに追加
ID 13511
Eprint ID
13511
FullText URL
Thumnail 116_9.pdf 4.1 MB
Author
垣下 幹夫
三浦 綾
久松 研一
伴場 主一
渡邊 敦之
藤尾 栄起
宮地 克維
永瀬 聡
森田 宏
斎藤 博則
江森 哲郎
浅沼 幹人
宮崎 正博
中村 陽一
松原 広己
伏見 和郎
豊國 伸哉
大江 透
Abstract
心不全患者において血中の過酸化脂質の上昇などが報告され,活性酸素による酸化ストレスの関与が示唆されている.そこで,心筋が実際に活性酸素を発生するかどうかを,活性酸素を検出する蛍光プローブを用いてラットの培養心筋細胞において検討した.心不全増悪因子であるアンジオテンシンIIおよびtumor necrosis factor(TNF)-alphaを加えると心筋細胞で濃度依存性に活性酸素が発生した.さらにヒトの不全心筋においても実際に酸化ストレスの発生が増強しているかを検討した.過酸化脂質の代謝産物で,有害なアルデヒドである4-Hydroxy-2-nonenal(HNE)によって修飾された蛋白質を免疫染色にて調べたところ,拡張型心筋症患者の心筋において正常心機能者に比べ5倍以上増加していた.さらにβ遮断薬(Carvedilol)により治療を行ったところ心機能の改善とともに,HNE修飾蛋白質が40%低下した.以上の一連の研究により, 活性酸素による酸化ストレスの発生が不全心筋において増強しており,その抑制が心不全治療のターゲットの一つになりうることを明らかにした.
Keywords
4-Hydroxy-2-nonenal
酸化ストレス
心不全
β遮断薬
Note
特別依頼原稿
Published Date
2004-05-31
Publication Title
岡山医学会雑誌
Publication Title Alternative
Journal of Okayama Medical Association
Volume
volume116
Issue
issue1
Publisher
岡山医学会
Publisher Alternative
Okayama Medical Association
Start Page
9
End Page
16
ISSN
0030-1558
NCID
AN00032489
Content Type
Journal Article
Official Url
https://www.jstage.jst.go.jp/article/joma1947/116/1/116_1_9/_article/-char/ja/
Related Url
http://www.okayama-u.ac.jp/user/oma/
References
1) Nakamura K, Matsumori A, Kusano KF, Banba K, Taniyama M, Nakamura Y, Morita H, Matsubara H, Yamanari H, Ohe T: Hepatitis C virus infection in a patient with dermatomyositis and left ventricular dysfunction. Jpn Circ J (2000) 64, 617-618.
2) Nakamura K, Kouchi H, Ohe T, Namba M: Increase in beating rate of cultured chick cardiac myocytes by ethanol and inhibition of the increase by antiarrhythmic drugs. Alcohol Clin Exp Res (1999) 23, S81-84.
3) Braunwald E, Bristow MR: Congestive heart failure: fifty years of progress. Circulation (2000) 102, IV14-23.
4) 中村一文, 垣下幹夫, 草野研吾, 伏見和郎, 宮崎正博, 難波正義, 大江透: TNF-αとアンギオテンシンHによる心筋細胞肥大と活性酸素の関与. フリーラジカルの臨床 (2000) 15, 50-54.
5) Belch JJ, Bridges AB, Scott N, Chopra M: Oxygen free radicals and congestive heart failure. Br Heart J (1991) 65, 245-248.
6) McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ: Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J (1993) 14, 1493-1498.
7) Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, Namba M: Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation (1998) 98, 794-799.
8) Kakishita M, Nakamura K, Asanuma M, Morita H, Saito H, Kusano K, Nakamura Y, Emori T, Matsubara H, Sugaya T, Ogawa N, Ohe T: Direct evidence for increased hydroxyl radicals in angiotenisn II-induced cardiac hypertrophy through angioteisin II type la receptor. J Cardiovasc Pharmacol (2003) 42, S67-70.
9) Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, Yamamoto M, Miyaji K, Saito H, Morita H, Emori T, Matsubara H, Toyokuni S, Ohe T: Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation (2002) 105, 2867-2871.
10) Uchida K, Stadtman ER: Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sci USA (1992) 89, 4544-4548.
11) Toyokuni S, Miyake N, Hiai H, Hagiwara M, Kawakishi S, Osawa T, Uchida K: The monoclonal antibody specific for the 4-hydroxy-2-nonenal histidine adduct. FEBS Lett (1995) 359, 189-191.
12) Uchida K: 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res (2003) 42, 318-343.
13) Toyokuni S: Reactive oxygen species-inducedmolecular damage and its application in pathology. Pathol Int (1999) 49, 91-102.
14) Eaton P, Li JM, Hearse DJ, Shattock MJ: Formation of 4-hydroxy-2-nonenal-modified proteins in ischemic rat heart. Am J Physiol (1999) 276, H935-943.
15) Haenen GR, Plug HJ, Vermeulen NP, Timmerman H, Bast A: Contribution of 4-hydroxy-2, 3-trans-nonenal to the reduction of beta-adrenoceptor function in the heart by oxidative stress. Life Sci (1989) 45, 71-76.
16) Bhatnagar A: Electrophysiological effects of 4-hydroxynonenal, an aldehydic product of lipid peroxidation, on isolated rat ventricular myocytes. Circ Res (1995) 76, 293-304.
17) Ishikawa T, Esterbauer H, Sies H: Role of cardiac glutathione transferase and of the glutathione S-conjugate export system in biotransformation of 4-hydroxynonenal in the heart. J Biol Chem (1986) 261, 1576-1581.
18) Benderdour M, Charron G, DeBlois D, Comte B, Des Rosiers C: Cardiac mitochondrial NADP+-isocitrate dehydrogenase is inactivated through 4-hydroxynonenal adduct formation: an event that precedes hypertrophy development. J Biol Chem (2003) 278, 45154-45159.
19) Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med (1984) 311, 819-823.
20) Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 82, 1724-1729.
21) Obata T, Yamanaka Y: Cardiac microdialysis of salicylic acid. OH generation on nonenzymatic oxidation by norepinephrine in rat heart. Biochem Pharmacol (1997) 53, 1375-1378.
22) Singal PK, Beamish RE, Dhalla NS: Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Adv Exp Med Biol (1983) 161, 391-401.
23) Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS: Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol (2002) 34, 379-388.
24) Xiao L, Pimentel DR, Wang J, Singh K, Colucci WS, Sawyer DB: Role of reactive oxygen species and NAD (P) H oxidase in alpha (1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol (2002) 282, C926-934.
25) Remondino A, Kwon SH, Communal C, Pimentel DR, Sawyer DB, Singh K, Colucci WS: Beta-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res (2003) 92, 136-138.
26) 中村一文, 垣下幹夫, 草野研吾, 三浦綾, 久松研一, 永瀬聡, 森田宏, 斉藤博則, 江森哲郎, 浅沼幹人, 小川紀雄, 宮崎正博, 中村陽一, 松原広己, 伏見和郎, 豊國伸哉, 大江透:β遮断薬と酸化ストレス. 心電図 (2004) 24, 15-21.
27) Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med (1996) 334, 1349-1355.
28) CIBIS- II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet (1999) 353, 9-13.
29) MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353, 2001-2007.
30) Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med (2001) 344, 1651-1658.
31) Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON, Eng C: Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation (1999) 99, 2645-2651.
32) Holmer SR, Kaissling B, Putnik K, et al.: Beta-adrenergic stimulation of renin expression in vivo. J Hypertens (1997) 15, 1471-1479.
33) Ohtsuka T, Hamada M, Hiasa G, Sasaki 0, Suzuki M, Hara Y, Shigematsu Y, Hiwada K: Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol (2001) 37, 412-417.
34) Ohtsuka T, Hamada M, Saeki H, Ogimoto A, Hiasa G, Hara Y, Shigematsu Y, Hiwada K: Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol (2002) 89, 996-999.
35) Nakamura K, Kakishita M, Kusano K, Nakamura Y, Nagase S, Ohta K, Miyaji K, Morita H, Emori T, Matsubara H, Ohe T: Elevated Levels of 4-Hydroxy-2-nonenal-modified Protein in Myocardium of Patients with Dilated Cardiomyopathy and Amelioration by Carvedilol. Circulation (2001) 104, II-661.
36) Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magsino CH Jr: Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation (2000) 101, 122-124.
37) Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, Takeshita A: Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res (1999) 85, 357-363.
38) Ide T, Tsutsui H, Kinugawa S, Suematsu N, Hayashidani S, Ichikawa K, Utsumi H, Machida Y, Egashira K, Takeshita A: Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res (2000) 86, 152-157.
39) Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G: Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther (1992) 263, 92-98.
40) Flesch M, Maack C, Cremers B, Baumer AT, Sudkamp M, Bohm M: Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation (1999) 100, 346-353.
41) Yuan Z, Shioji K, Kihara Y, Takenaka H, Onozawa Y, Kishimoto C: Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Am J Physiol Heart Circ Physiol (2004) 286, H83-90.
42) Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A; Carvedilol Or Metoprolol European Trial Investigators: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 362, 7-13.
language
日本語
Copyright Holders
Copyright© 岡山医学会
File Version
publisher
Refereed
True
Eprints Journal Name
joma